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Introduction. On follow up MRI studies in patients with GB, it is difﬁcult to differentiate between treatment side effects or tumor
progression. Radiation induces changes in brain parenchyma that may mimic tumor recurrence or progression, and concomi-
tant treatment with temozolomide due to the radiosensitizer effect can increase those changes. Therefore MR images after
treatment are difﬁcult to interpret. We studied radiation-induced changes in normal white matter to deﬁne what changes might
be attributable to radiotherapy.
Material and Methods. We analyzed magnetic resonance imaging (MRI) perfusion studies in 9 patients who have undergone com-
plete tumor resection. MRI was performed on a 3T Unit (Siemens) using the susceptibility perfusion technique. We quantiﬁed
the rCBV drawing four regions of interest (ROI) in normal white matter located in: ROI90 (area of high isodose (90–100%)); ROI50
(area of medium isodose (50–90%)); ROI30 (area of low isodose (30–50%); and ROI0 (In white matter not receiving radiation). Quan-
tiﬁcation was performed on MRI studies in the middle of radiation treatment, at the end of radiation treatment, and 4 weeks
after completing the treatment.
Results. We found an increase in rCBV in normal white matter that received radiation. This increase was greater in areas of
maximum irradiation. These changes were seen in all follow-up studies. We observed changes in the rCBV, even in the range of
lower doses of irradiation, when the doses delivered corresponded to 6–9Gy.
Conclusions. Our study shows changes in the rCBV of normal white matter. These changes can tell us about the likelihood of
toxicities and can help in assessment of treatment response.
http://dx.doi.org/10.1016/j.rpor.2013.03.730
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Introduction. From 2011 we started our clinical IMRT treatments (IMRT), either “step and shoot” or VMAT (Volumetric Modulated
Arc Therapy). We decided to use for the treatment an altered fractionation with “integrated boost” and Temozolamide.
Objectives. Our goal is to analyze the ﬁrst patients with high grade glioma with this protocol, feasibility, tolerance and treatment
outcomes. Method Eight patients (4 men and 4 women), mean age 56 (43–69) years, were enrolled between May 2011 and October
2012. Two cases with AA (anaplasic astrocytoma), three cases with GM (multiforme glioblastoma), a case with anaplasic oligoden-
droglioma (AO), a case with low-grade glioma that had progressed radiologically to high grade but no biopsy and the last patient
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with radiologic diagnostic of high grade glioma without biopsy. We contour a CTV1 with 2–2.5 cm and a CTV2 with 1–1.5 cm of
margin at GTV. Expansion of GTV to CTVs not including anatomical barriers. For PTVs (PTV1 and PTV2) we add 3mm to CTV.
Image-guided radiation therapy (IGRT) is used. The squeme of “integrated boost” is: 25 fractions of 1.9Gy/day (total dose 45.5Gy)
for PTV1 and 2.3Gy/day (total dose 57.5Gy) for PTV1, 5 days a week.
Results. All patients have completed treatment. Median follow-up was 9 months (1–19 months) and median overall survival 9
months (1–19 months). Two patients with GM and AA have died at 6 and 4.5 months due to tumoral progression.
Conclusions. Although the series is small, acute toxicity was similar to the conventional treatments. The radiotherapy has been
completed as planned. With the integrated boost technique involves a higher doses per fraction that achieves a higher biological
effective and more local control. Total treatment time take ﬁve weeks. It is presume to involve an increase in survival, longer
follow up is require.
http://dx.doi.org/10.1016/j.rpor.2013.03.731
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Background. We present a mathematical model for grade II glioma progression and response to radiotherapy (RT) able to predict
the long-time response to treatment.
Materials and methods. The model describes the evolution of the tumor cell density as a function of time-space incorporating: (i)
tumor cell inﬁltration, as diffusion coefﬁcient D accounting for the cellular motility measured in mm2/day and (ii) proliferation
with an average rate r (1/day). The response to radiation is modelled as the evolution of the density of damaged cells that are
assumed to complete an average number of k mitosis before dying [Typical parameters: diffusion around 0.0075 mm2/day and
proliferation rates in the range r=0.01–0.001 day−1]. The fraction of tumor cells damaged by a radiation dose is estimated by the
L-Q model. Different radiotherapy schemes were simulated including the standard one of 54Gy in 30 fractions of 1.8Gy over a
time range of 6 weeks.
Results. The model output was compared with recently published clinical results (Pallud et al, Neuro-Oncology, 2012) and with
those of clinical trials (Van den Bert et al, Lancet, 2005; Shaw et al, J. Clin. Oncol., 2002) with excellent agreement. Proliferation
rates determine the response to RT. The smaller the proliferation rate, the longer the progression-free interval and survival rates.
Highly proliferative tumors respond earlier to RT but bear an adverse prognosis. Cell motility does not signiﬁcantly affect early
response, but has a relevant impact on survival. Deferring radiotherapy or splitting doses does not affect survival. This concept
justiﬁes splitted treatment strategies. The response of the tumor can be fed into the model to provide information regarding
proliferation rate and rough estimates for the time of transition to malignancy. The mathematical analysis of the model also
gives an equation for the tumor time of birth.
Conclusions. The model provides an explanation to published observations and suggests novel radiation therapy strategies poten-
tially useful.
http://dx.doi.org/10.1016/j.rpor.2013.03.732
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Background. High-grade gliomas (III and IV) are not curable tumors and they have a poor prognosiswith consensus or experimental
treatments. Molecular biology markers could help us to predict response to chemoradiotherapy and evolution of the disease in
each patient.
Objectives. This prospective study aims to evaluate the relationship between IDH1 (isocitrate deshydrogenase-1) mutation and
MGMT methylguanine-DNA methyltransferase) methylation and overall and disease-free survival. Methods: We included all
patients diagnosed with multiform glioblastoma GBM) and anaplastic astrocytoma (AA) treated with surgery followed by
chemoradioterapy. Radiotherapy (RT) consisted in 60Gy in two phases with conventional schedule. Variables: IDH1-mutation
(ampliﬁcation throughPCRand sequencing),MGMT-methylation (methylation-speciﬁc PCRassay), anatomopathology, Karnofsky,
surgery, chemotherapy. Overall and disease-free survival was estimated with the Kaplan-Meier method.
Results. Between November 2010 and June 2012, there were 38 patients. 60% men, 56 years old average. Men were younger (8 years)
than women. 24 GBM, 10 AA and 4 with GBM-AA mixed. 84% had more than 80% Karnofsky. 6 biopsied, 24 partial resections
and 8 large resections/lobectomies. 83% of GBM and mixed were treated with surgery, RT and concomitant temozolamide.
60% of AA were treated with surgery, RT and sequential PCV. 17 were MGMT-methylation (59%GBM, 23,5%AA) and 5 were IDH1-
